Marco studied biochemistry in Berlin and Tübingen and eventually obtained his PhD in chemical biology. He began exploring human genetics for drug development and what is now called machine learning at the University of Cambridge, UK, which led to the founding of biotx.ai GmbH. The company has causally maps the entire genome in order to find new treatmemts and to simulate clinical trials, and this technology is now being made available to biotech and pharmaceutical companies. He is also known for his textbook 'Chemical Biology & Drug Discovery'.
Recent articles from Marco
Is There an "Innovator's Dilemma" in Biotech?
The term "Innovator's Dilemma" was coined by Clayton Christensen in 1997. The Innovator's Dilemma refers to a situation where successful, well-established companies face challenges in adopting and integrating new and innovative technologies or business models, despite their proven success in …